ERBB2 and breast cancer: Gaynor et al. [41], in the phase II neoadjuvant clinical trial ICORG10-05 (NCT01485926), compared immune cell profiles in HER2+ BC patients treated with chemotherapy with trastuzumab, lapatinib, or both.